Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Larsimont

Showing results (91-100 of 100) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 100 results.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|July 22, 2008
Clinical validation of a molecular assay for intra-operative detection of metastases in breast sentinel lymph nodesM D Martin Martinez, I Veys, S Majjaj, et al.
British Journal of Cancer|June 13, 2015
SNPs at miR-155 binding sites of TYRP1 explain discrepancy between mRNA and protein and refine TYRP1 prognostic value in melanomaP El Hajj, D Gilot, M Migault, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 4, 2014
Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancerF Rothé, J-F Laes, D Lambrechts, et al.
ESMO Open|May 4, 2024
The long and winding road to biomarkers for immunotherapy: a retrospective analysis of samples from patients with triple-negative breast cancer treated with pembrolizumabL Buisseret, Y Bareche, D Venet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2001
HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamideA Di Leo, D Larsimont, D Gancberg, et al.
Breast Cancer Research and Treatment|November 30, 2004
HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxelA Di Leo, S Chan, M Paesmans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 8, 2013
Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trialC Oakman, P A Francis, J Crown, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 28, 2016
Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancersD Fumagalli, T R Wilson, R Salgado, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 3, 2012
Genomic grade adds prognostic value in invasive lobular carcinomaO Metzger-Filho, S Michiels, F Bertucci, et al.
Genomics Data|October 21, 2015
Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patientsB Haibe-Kains, C Desmedt, A Di Leo, et al.
Pageof 10

Showing results (91-100 of 100) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 100 results.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|July 22, 2008
Clinical validation of a molecular assay for intra-operative detection of metastases in breast sentinel lymph nodesM D Martin Martinez, I Veys, S Majjaj, et al.
British Journal of Cancer|June 13, 2015
SNPs at miR-155 binding sites of TYRP1 explain discrepancy between mRNA and protein and refine TYRP1 prognostic value in melanomaP El Hajj, D Gilot, M Migault, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 4, 2014
Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancerF Rothé, J-F Laes, D Lambrechts, et al.
ESMO Open|May 4, 2024
The long and winding road to biomarkers for immunotherapy: a retrospective analysis of samples from patients with triple-negative breast cancer treated with pembrolizumabL Buisseret, Y Bareche, D Venet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2001
HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamideA Di Leo, D Larsimont, D Gancberg, et al.
Breast Cancer Research and Treatment|November 30, 2004
HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxelA Di Leo, S Chan, M Paesmans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 8, 2013
Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trialC Oakman, P A Francis, J Crown, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 28, 2016
Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancersD Fumagalli, T R Wilson, R Salgado, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 3, 2012
Genomic grade adds prognostic value in invasive lobular carcinomaO Metzger-Filho, S Michiels, F Bertucci, et al.
Genomics Data|October 21, 2015
Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patientsB Haibe-Kains, C Desmedt, A Di Leo, et al.
Pageof 10